The application of modern fluoroquinilones for the treatment of bacterial eye infections in the young children


Cite item

Full Text

Abstract

The results of the ophthalmological observation of 50 (63.3%) children at the age from 1 to 29 days and 29 (36.7%) ones at the age from 1 to 12 months are reported. 62 (78.5%) patients presented with the signs of bacterial conjunctivitis while the remaining 17 (21.5%) ones suffered from suppurative dacryocystitis. We studied the microflora from the conjunctival space of these 79 children. The Gram-positive bacteria St. epidermidis (59.7%) and St. aureus (21.7%) were found to play the leading role in the development of inflammatory eye diseases. The study of sensitivity and resistance of the antibacterial preparations to the isolated pathogens showed that fluoroquinolones exhibit the highest therapeutic effectiveness. The 0.5% moxifloxacin eye drops caused positive dynamics of the clinical course of inflammatory eye diseases in the newborn and young children. Specifically, inflammation was totally eliminated in the patients presenting with bacterial conjunctivitis and in 71% of those with suppurative dacryocystitis. The authors recommend to use Vigamox eye drops for the wide application in the pediatric ophthalmological practice. However, this preparation can be prescribed to the children under 1 year of age only after obtaining the voluntary informed consent of the parents.

About the authors

El’vira Irekovna Saidasheva

State Budgetary Educational Institution of Higher Professional Education «I.I. Mechnikov North-West State Medical University»; State budgetary healthcare facility «Children's City Clinical Hospital No 1»

Email: esaidasheva@mail.ru
Department of Pediatric Opthalmology 198205, Sankt-Petersburg, Russia

S. V Buyanovskaya

State Budgetary Educational Institution of Higher Professional Education «I.I. Mechnikov North-West State Medical University»; State budgetary healthcare facility «Children's City Clinical Hospital No 1»

Department of Pediatric Opthalmology 198205, Sankt-Petersburg, Russia

F. V Kovshov

State Budgetary Educational Institution of Higher Professional Education «I.I. Mechnikov North-West State Medical University»; State budgetary healthcare facility «Children's City Clinical Hospital No 1»

Department of Pediatric Opthalmology 198205, Sankt-Petersburg, Russia

I. V Gudimova

State budgetary healthcare facility «Children's City Clinical Hospital No 1»

198205, Sankt-Petersburg, Russia

E. A Fanta

State budgetary healthcare facility «Children's City Clinical Hospital No 1»

198205, Sankt-Petersburg, Russia

L. N Chetvernya

State budgetary healthcare facility «Children's City Clinical Hospital No 1»

198205, Sankt-Petersburg, Russia

N. P Dubok

State budgetary healthcare facility «Children's City Clinical Hospital No 1»

198205, Sankt-Petersburg, Russia

References

  1. Сайдашева Э.И., Любименко В.А., Котина Н.З. Инфекционные заболевания глаз у новорожденных детей (современные методы диагностики и лечения): Методические рекомендации. СПб.: Реноме; 2009.
  2. Катаргина Л.А., Арестова Н.Н., Старикова А.В., Гвоздюк Н.А. Рекомендации по лечению врожденной патологии слезоотводящих путей (дакриоцистит новорожденных, дакриоцистоцеле, врожденный стеноз слезоотводящих путей) у новорожденных и детей раннего возраста: Пособие для врачей. М.: Самполиграфист; 2012.
  3. Wagner R.S., Abelson M. et al. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin and levofloxacin concentrations in human conjunctival tissue. Arch. Ophthal. 2005; 123: 1282-3.
  4. Чекина А.Ю. Первый отечественный опыт применения глазных капель моксифлоксацина в амбулаторной офтальмологической практике. Офтальмология в Беларуси. 2010; 3 (06): 20-2.
  5. Зубарева Л.Н., Гаврилюк А.С., Артамонова А.В. Первый опыт клинического применения глазных капель Вигамокс у пациентов детского возраста. Новое в офтальмологии. 2011; 4: 66-7.
  6. Gross R.D., Silas P., Oshman S. et al. A comparison of the safety and efficacy of moxifloxacin and ciprofloxacin in the treatment of presumed bacterial conjunctivitis in neonatal patients. Invest. Ophthal. Vis. Sci. 2003; 44: 1465.
  7. Silver L.H., Burkey R., Montgomery D. et al. Safety of Ophthalmic moxifloxacin in the treatment of newborns, infants and toddlers, children, and adolescents with bacterial conjunctivitis. Invest. Ophthal. Vis. Sci. 2003; 44: 804.
  8. Wagner R.S., D’Arienzo P.A., Hallas S.J., Thomson M.B., Shapiro A.M. A comparative study in a normal pediatric population of the relative comfort of moxifloxacin 0,5% ophthalmic solution versus a tear substitute. Presented at Association for Research in Vision and Ophthalmology. April 29, 2004.

Copyright (c) 2015 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies